News

Expansion of distribution partnership in Europe

Actylis and Novo Nordisk Pharmatech are expanding their strategic partnership for the distribution of Benzalkonium Chloride in targeted European countries.

Køge, January 20, 2025

Actylis and Novo Nordisk Pharmatech are currently partnering for the distribution of cGMP-grade Benzalkonium Chloride (BKC) to the pharmaceutical and medical device markets in Canada, Germany, Spain, Portugal, the UK, and Ireland. This successful partnership will now be extended to a series of new territories: the Nordics (Denmark, Norway, Sweden and Finland), Benelux (Belgium, The Netherlands and Luxembourg) and France.

By combining Novo Nordisk Pharmatech’s leading position to manufacture the highest standards of pharmaceutical grade Benzalkonium Chloride (BKC/BAK), with Actylis’ expertise and infrastructures dedicated to critical raw material distribution, we aim to provide our customers with the best end-to-end service and quality.

 

Statement from Actylis: “We are delighted to grow our partnership with Novo Nordisk Pharmatech and expand our footprint across these important regions. This is a testament to the shared commitment between our organizations to deliver exceptional quality and service to meet the evolving needs of our customers, we look forward to continuing this momentum into an exciting 2025” says Damien O’Rourke, President, Global Pharma at Actylis.

 

Statement from Novo Nordisk Pharmatech: “Building on the success of our partnership in established territories, we are excited to elevate our collaboration with Actylis to new heights. This will bolster our commitment to excellence in the European market and enhance our support for customers in the newly incorporated countries. We look forward to continuing a successful partnership in the years ahead,” says Samia Kappe, Chief Commercial Officer at Novo Nordisk Pharmatech.

 

About Actylis: Actylis is a global solutions provider with over 75 years of experience, specializing in streamlining the management of critical ingredients and raw materials for our business partners in pharmaceutical and biopharmaceutical industries. We offer both sourcing and manufacturing solutions tailored to meet diverse and evolving needs, ensuring a reliable, agile, and secure supply network. Our commitment to customization allows us to create flexible solutions, whether it’s a unique specification, custom packaging, or tailored logistics strategies. With deep expertise in quality and regulatory compliance, sourcing and logistics management, analytical services, and R&D support, we reduce complexities and mitigate risks, empowering our partners to focus on growing their business.

 

About Novo Nordisk Pharmatech: Novo Nordisk Pharmatech is a global and leading manufacturer of pharmaceutical ingredients for the pharmaceutical and biopharmaceutical industries. The company specializes in Quats (Benzalkonium Chloride) used as active pharmaceutical ingredients (APIs) and excipients in the highest available quality standard – and pharmaceutical grade Recombinant Insulin and Trypsin (TrypsiNNex®) for use in cell-based biopharmaceutical processes.

 

The Benzalkonium Chloride products comply with the latest pharmacopeial standards and are extensively supported by CEPs, DMFs and a comprehensive regulatory and quality assurance document package. In addition, the manufacturing site in Køge (Denmark) is audited by the Danish Medicines Agency and US FDA.

Posted

Explore more